

| Double-blind | peer revie | w submis  | sions: write |
|--------------|------------|-----------|--------------|
| DBPR and vo  | ur manusc  | ript numb | per here     |

Corresponding author(s): instead of author names.

Last updated by author(s): YYYY-MM-DD

# **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

| _ |    |    |     |     |
|---|----|----|-----|-----|
| 5 | ta | ŤΙ | ıst | ics |

X Life sciences

| Statistics  |  |  |
|---|--|--|
| For all statistical analyses  | s, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.   |  |
| n/a Confirmed   |  |  |
|   | ole size (n) for each experimental group/condition, given as a discrete number and unit of measurement  Should report number of wells that are tested in each treatment group  whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |  |
| 1 111 1 1 1   | The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.  |  |
| A description of  | f all covariates tested  |  |
| A full description  | f any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  Adjustment for multiple comparisons is likely necessary and should be reported on of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |  |
| For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i> No indication of null hypothesis testing, should report null hypothesis stats |  |  |
| NA For Bayesian ar  | NA For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |  |
| NA For hierarchical   | and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |  |
| <b>X</b> Estimates of eff   | fect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated  Estimates of effect sizes should be reported  Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.   |  |
| Software and co   | ode  |  |
| Policy information about  | availability of computer code  |  |
|   | Lifespan data was collected by noting when individuals passed away or didn't pass away. Calcium imaging data was recorded by measuring floresence emission   |  |
|   | STATA was used for data analysis rcial, open source and custom code used to analyse the data in this study, specifying the version used OR state that no software was used.  |  |
|   | n algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. eposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.   |  |
| Data  |  |  |
| - Accession codes, uniq<br>- A list of figures that ha  | t availability of data clude a data availability statement. This statement should provide the following information, where applicable: que identifiers, or web links for publicly available datasets ave associated raw data estrictions on data availability  |  |
| Raw data should be made available in a public domain  |  |  |
| Field-specif  | cic reporting  |  |

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Ecological, evolutionary & environmental sciences

Behavioural & social sciences

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

Rationale for how sample size was determined is needed, justification for why these sample sizes were sufficient also need be included. *Size calculation* was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

Data exclusions

**Excluded data from wells with more than 19 individuals; however rationale for the decision needs to be included.** 2d, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Replication

Measures taken to verify reproducibility need to be included. of the experimental findings. If all attempts at replication were successful, confirm this OR if there are any findings that were not replicated or cannot be reproduced, note this and describe why.

Randomization

Information on how animals were separated should be included ed into experimental groups. If allocation was not random, describe how covariates were controlled OR if this is not relevant to your study, explain why.

Blinding

Details about investigator blinding should be included a group allocation during data collection and/or analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

# Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).

Research sample

State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.

Sampling strategy

Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.

Data collection

Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.

Timing

Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.

Data exclusions

If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Non-participation

State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.

Randomization

If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

## Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.

Research sample

Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.

Sampling strategy

Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

| Data Collection                       | Describe the data conection procedure, including who recorded   | the data and now.  |
|---------------------------------------|---|--|
| Timing and spatial scale              |   | requency and periodicity of sampling and providing a rationale for<br>the dates for each sample cohort. Specify the spatial scale from which |
| Data exclusions                       | If no data were excluded from the analyses, state so OR if data indicating whether exclusion criteria were pre-established.   | were excluded, describe the exclusions and the rationale behind them,  |
| Reproducibility                       | Describe the measures taken to verify the reproducibility of experence the experiment failed OR state that all attempts to repec  | erimental findings. For each experiment, note whether any attempts to at the experiment were successful.                                     |
| Randomization                         | Describe how samples/organisms/participants were allocated ir controlled. If this is not relevant to your study, explain why.   | nto groups. If allocation was not random, describe how covariates were   |
| Blinding                              | Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why olinding was not relevant to your study. |  |
| Did the study involve field           |   |  |
| Field Work, collect                   | ion and transport   |  |
| Field conditions                      | Describe the study conditions for field work, providing relev   | ant parameters (e.g. temperature, rainfall).   |
| Location                              | State the location of the sampling or experiment, providing depth).   | relevant parameters (e.g. latitude and longitude, elevation, water   |
| Access and import/export              |   | to collect and import/export your samples in a responsible manner and oting any permits that were obtained (give the name of the issuing n). |
| Disturbance                           | Describe any disturbance caused by the study and how it w   | as minimized.  |
| We require information from a         |   | d methods used in many studies. Here, indicate whether each material ir research, read the appropriate section before selecting a response.  |
| Materials & experimen                 |   |  |
| n/a Involved in the study  Antibodies | n/a Involved in the study   |  |
| Eukaryotic cell lines                 | ChIP-seq    Chip-seq   Flow cytometry   |  |
| X Palaeontology                       | MRI-based neuroimagin   | g  |
| Animals and other or                  |   |  |
| Human research par                    | icipants  |  |
| Clinical data                         |   |  |
| Antibodies                            |   |  |
| Antibodies used                       | DeNAe all antibodies used in the study; as applicable, pro  | vide supplier name, catalog number, clone name, and lot number.  |
| Validation                            | Describe the validation of each primary antibody for the sp<br>manufacturer's website, relevant citations, antibody profile   | ecies and application, noting any validation statements on the<br>s in online databases, or data provided in the manuscript.                 |
| Eukaryotic cell line                  | es  |  |
| Policy information about <u>ce</u>    | l lines   |  |
| Cell line source(s)                   | MA the source of each cell line used.   |  |
| Authentication                        | Ns∆ibe the authentication procedures for each cell line   | e used OR declare that none of the cell lines used were authenticated.   |

Canfirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

Mycoplasma contamination

### Palaeontology

Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition

In Make where the specimens have been deposited to permit free access by other researchers.

Dating methods

If Madates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

### Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals Caenorhabditis elegans, birth-death that the study did not involve laboratory animals.

Wild animals

None tails on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals ht and transported and what happened to captive animals after the study (if killed, explain why and describe method; if

released, say where and when) OR state that the study did not involve wild animals.

Field-collected samples

None tory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, and and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

Ethics oversight

No oversight approval was mentioned, should report the study protocol, OR state that no ethical approval or if it was granted or why it is not necessary

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Human research participants

Population characteristics

Policy information about studies involving human research participants

oney information about <u>studies involving numum rescuren participants</u>

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment Describe how participants were recruited. Outlin

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

#### Clinical data

Study protocol

Clinical trial registration

Ethics oversight

Policy information about clinical studies

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

Note where the full trial protocol can be accessed OR if not available, explain why.

Identify the organization(s) that approved the study protocol.

Data collection

Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

#### ChIP-seq

#### Data deposition

| Confirm that both raw and final processed data have been deposited in a public database such as GEO      | Data is not public |
|--|--------------------|
| Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks. | Data is not public |

#### Data should be made public version" documents, provide reviewer access links. For your "Final submission" document, Data access links May remain private before publication. Data should be made public the database submission. Files in database submission NA ide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only. to Genome browser session (e.g. UCSC) ການປະຊານ le peer review. Write "no longer applicable" for "Final submission" documents. Methodology Experimental replicates should be reported or, type and replicate agreement. Replicates NA ribe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of Sequencing depth as and whether they were paired- or single-end. NA ribe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone Antibodies name, and lot number. NA ify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and Peak calling parameters muex files used. NA ribe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold Data quality NA ribe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a Software munity repository, provide accession details. Flow Cytometry **Plots** Confirm that: The axis labels state the marker and fluorochrome used (e.g. CD4-FITC). The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers). All plots are contour plots with outliers or pseudocolor plots. A numerical value for number of cells or percentage (with statistics) is provided. Methodology Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used. Sample preparation Identify the instrument used for data collection, specifying make and model number. Instrument Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a Software community repository, provide accession details. Cell population abundance Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell Gating strategy population, indicating where boundaries between "positive" and "negative" staining cell populations are defined. Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

#### Experimental design

Design type Indicate task or resting state; event-related or block design.

Design specifications

Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

of block (ij thats are blocked) and interval between the

Behavioral performance measures

State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

Data is not public

| Acquisition  |   |  |  |
|--|---|--|--|
| Imaging type(s)  | Specify: functional, structural, diffusion, perfusion.  |  |  |
| Field strength   | Specify in Tesla  |  |  |
| Sequence & imaging parameters  | Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.  |  |  |
| Area of acquisition  | State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.  |  |  |
| Diffusion MRI Used   | lsed Not used   |  |  |
| Parameters Specify # of  | directions, b-values, whether single shell or multi-shell, and if cardiac gating was used.  |  |  |
| Preprocessing  |   |  |  |
| Preprocessing software   | Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).   |  |  |
| Normalization  | If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization. |  |  |
| Normalization template   | Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.                             |  |  |
| Noise and artifact removal   | Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).   |  |  |
| Volume censoring   | Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.   |  |  |
| Statistical modeling & inference   | e   |  |  |
| Model type and settings  | Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).                        |  |  |
| Effect(s) tested   | Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.  |  |  |
| Specify type of analysis: Whole  | e brain ROI-based Both  |  |  |
| Anatomi  | cal location(s) Describe how anatomical locations were determined (e.g. specify whether automated labeling algorithms or probabilistic atlases were used).  |  |  |
| Statistic type for inference (See <u>Eklund et al. 2016</u> )  | Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.   |  |  |
| Correction   | Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).  |  |  |
| Models & analysis  |   |  |  |
| n/a Involved in the study  Functional and/or effective co  Graph analysis  Multivariate modeling or pred |   |  |  |
| Functional and/or effective connect  | Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).   |  |  |
| Graph analysis   | Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).               |  |  |



Specify independent variables, features extraction and dimension reduction, model, training and evaluation

metrics.

Multivariate modeling and predictive analysis